We’re the leading resource for West Virginians affected by bleeding disorders. You can count on WVNHF to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
BIVV001 is a novel, investigational recombinant factor VIII therapy developed for the prevention of bleeding episodes in hemophilia A patients via once weekly prophylactic infusions.
Your input will ensure that NHF is meeting your needs.
Mononine ® was first introduced as treatment available to hemophilia B patients in 1992.
The National Hemophilia Foundation will be holding our quarterly Board of Directors meeting on Saturday, October 10th at 9:00 AM EDT.
Hemlibra® is a subcutaneous injection currently indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A with or without factor VIII inhibitors.
Subscribe to Our Newsletter
Fill in the fields below to receive our email newsletter.